Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

v3.10.0.1
Intangibles, net (Tables) - Journey Medical Corporation [Member]
9 Months Ended
Sep. 30, 2018
Schedule of Finite-Lived Intangible Assets
 
 
Estimated Useful
Lives (in years)
 
Cost
 
Ceracade®
 
3
 
$
300
 
Luxamend®
 
3
 
 
50
 
Targadox®
 
3
 
 
1,250
 
Exelderm®
 
3
 
 
1,200
 
Total
 
 
 
$
2,800
 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The carrying amount related to acquired intangible assets as of September 30, 2018 are as follows ($ in thousands):
 
 
Intangible assets at December 31, 2017
 
$
883
 
Addition
 
 
1,200
 
Amortization expense
 
 
(433
)
Intangible assets at September 30, 2018
 
$
1,650